Coral Laboratories Limited
BSE: CORALAB
Prev Close
440.75
Open Price
442.6
Volume
3,244
Today Low / High
440 / 472.95
52 WK Low / High
415 / 784.55
Range
430 - 475
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 452.7, reflecting a change of 11.95 (2.71129%). The expected target range on the BSE is 430 - 475. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Coral Laboratories Limited Graph
Coral Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Coral Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 452.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 452.70 | 457.23 | 411.50 - 502.95 |
| 461.75 | 369.40 - 554.10 | ||
| 466.28 | 326.40 - 606.17 | ||
| Bearish Scenario | 452.70 | 448.17 | 403.36 - 492.99 |
| 443.65 | 354.92 - 532.38 | ||
| 439.12 | 307.38 - 570.85 |
Overview of Coral Laboratories Limited
ISIN
INE683E01017
Industry
Medical - Pharmaceuticals
Vol.Avg
1,812
Market Cap
1,534,074,440
Last Dividend
1.5
Official Website
IPO Date
2001-12-31
DCF Diff
-127.89
DCF
557
Financial Ratios Every Investor Needs
Stock Dividend of CORALAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-19 | September 19, 25 | 1.5 | 1.5 | 2025-09-19 | 2025-10-26 | |
| 2024-09-20 | September 20, 24 | 2 | 2 | 2024-09-20 | 2024-10-27 | |
| 2019-09-19 | September 19, 19 | 2 | 2 | 2019-09-20 | 2019-10-27 | |
| 2018-09-18 | September 18, 18 | 2 | 2 | 2018-09-20 | 2018-10-27 | |
| 2017-09-11 | September 11, 17 | 5 | 5 | 2017-09-12 | 2017-10-19 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 115.01 Cr | 69.77 Cr | 45.24 Cr | 0.3934 | 0.00 Cr | 14.74 Cr | 24.23 Cr | 24.16 Cr | 67.62 | 34.58 Cr | 0.2100 |
| 2024-03-31 | 82.10 Cr | 40.35 Cr | 41.75 Cr | 0.5086 | 0.00 Cr | 4.02 Cr | 14.26 Cr | 15.79 Cr | 44.19 | 22.71 Cr | 0.1923 |
| 2023-03-31 | 77.89 Cr | 49.26 Cr | 28.63 Cr | 0.3676 | 0.00 Cr | 1.74 Cr | 1.63 Cr | 6.45 Cr | 18.04 | 10.74 Cr | 0.0827 |
| 2022-03-31 | 73.22 Cr | 42.64 Cr | 30.58 Cr | 0.4176 | 0.00 Cr | 2.56 Cr | 6.22 Cr | 9.05 Cr | 25.32 | 13.99 Cr | 0.1235 |
| 2021-03-31 | 95.21 Cr | 53.74 Cr | 41.47 Cr | 0.4356 | 0.00 Cr | 3.61 Cr | 13.87 Cr | 13.55 Cr | 37.94 | 19.86 Cr | 0.1424 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.41 Cr | 229.46 Cr | 28.26 Cr | 201.2058 Cr | 3.56 Cr | 0.15 Cr | 9.87 Cr | 24.23 Cr | 0.00 Cr | 0.00 Cr | 27.90 Cr | 24.9575 Cr |
| 2024-03-31 | 2.07 Cr | 205.68 Cr | 28.18 Cr | 177.4966 Cr | 0.00 Cr | -2.07 Cr | 15.16 Cr | 23.27 Cr | 0.00 Cr | 0.00 Cr | 27.43 Cr | 24.8992 Cr |
| 2023-03-31 | 6.13 Cr | 174.35 Cr | 19.55 Cr | 154.7981 Cr | 0.00 Cr | -6.13 Cr | 12.50 Cr | 24.28 Cr | 0.00 Cr | 0.00 Cr | 18.72 Cr | 11.8603 Cr |
| 2022-03-31 | 2.51 Cr | 189.90 Cr | 33.84 Cr | 156.0531 Cr | 6.04 Cr | 3.53 Cr | 18.36 Cr | 24.49 Cr | 0.00 Cr | 0.00 Cr | 2.67 Cr | 25.5176 Cr |
| 2021-03-31 | 2.32 Cr | 167.54 Cr | 30.90 Cr | 136.6433 Cr | 6.25 Cr | 3.93 Cr | 21.67 Cr | 20.91 Cr | 0.00 Cr | 0.00 Cr | -4.99 Cr | 27.5647 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -1.2223 Cr | -0.1520 Cr | 2.7083 Cr | -4.1673 Cr | 1.3340 Cr | 3.4054 Cr | -2.9450 Cr | 24.1556 Cr | 3.5204 Cr | -0.7145 Cr | 5.2855 Cr |
| 2024-03-31 | 23.0389 Cr | 1.3991 Cr | 0.0066 Cr | 22.0479 Cr | -4.0590 Cr | 2.0714 Cr | -0.9910 Cr | 15.7890 Cr | 0.0068 Cr | 0.0000 Cr | -2.6529 Cr |
| 2023-03-31 | 12.6652 Cr | -2.6147 Cr | -6.4261 Cr | 10.7198 Cr | 3.6244 Cr | 6.1304 Cr | -1.9454 Cr | 8.1880 Cr | -6.0876 Cr | 0.0000 Cr | 5.8584 Cr |
| 2022-03-31 | 6.0837 Cr | -6.0513 Cr | 0.1491 Cr | 0.5354 Cr | 0.1815 Cr | 2.5060 Cr | -5.5483 Cr | 10.8963 Cr | 0.2903 Cr | 0.0000 Cr | 3.3126 Cr |
| 2021-03-31 | 0.9309 Cr | -0.0681 Cr | 0.3500 Cr | -0.4293 Cr | 1.2128 Cr | 2.3245 Cr | -1.3602 Cr | 17.5937 Cr | 0.3417 Cr | 0.0000 Cr | -2.3762 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 21.56 Cr | 13.77 Cr | 7.79 Cr | 0.3614 | 1.20 Cr | 2.78 Cr | 7.77 | 1.89 Cr | 0.1287 |
| 2025-09-30 | 19.03 Cr | 7.55 Cr | 11.48 Cr | 0.6033 | 4.49 Cr | 5.82 Cr | 16.29 | 7.97 Cr | 0.3058 |
| 2025-06-30 | 18.82 Cr | 8.74 Cr | 10.08 Cr | 0.5358 | 1.73 Cr | 2.56 Cr | 7.18 | 4.23 Cr | 0.1362 |
| 2025-03-31 | 28.13 Cr | 14.57 Cr | 13.56 Cr | 0.4821 | 2.18 Cr | 2.83 Cr | 7.91 | 4.40 Cr | 0.1005 |
| 2024-12-31 | 22.99 Cr | 9.47 Cr | 13.52 Cr | 0.5882 | 5.81 Cr | 6.14 Cr | 17.20 | 8.84 Cr | 0.2673 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.33 Cr | 100.99 Cr | 102.32 Cr | 26.64 Cr | 12.08 Cr | 164.37 Cr | 36.63 Cr | 232.87 Cr | 19.78 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 107.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -201.21 Cr |
| 2025-03-31 | 3.41 Cr | 27.54 Cr | 30.95 Cr | 33.88 Cr | 9.87 Cr | 176.55 Cr | 24.23 Cr | 229.46 Cr | 28.26 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 91.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -203.55 Cr |
| 2024-09-30 | 0.97 Cr | 27.09 Cr | 91.26 Cr | 39.20 Cr | 12.96 Cr | 169.04 Cr | 22.43 Cr | 231.61 Cr | 28.06 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 2.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 6.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 6.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 8.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹830.35 | ₹99,644,807,413.00 | ₹76,499.00 |
Key Executives
Gender: male
Year Born: 1981
Gender: female
Year Born:
Gender: female
Year Born: 1981
FAQs about Coral Laboratories Limited
The CEO is Girish Madanlal Dhameja.
The current price is ₹429.40.
The range is ₹415-796.95.
The market capitalization is ₹153.41 crores.
The dividend yield is 0.35%.
The P/E ratio is 10.97.
The company operates in the Healthcare sector.
Overview of Coral Laboratories Limited (ISIN: INE683E01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹153.41 crores and an average daily volume of 1,812 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹1.5.